文献速递脊柱外科

微创腰椎减压术后应用甲泼尼龙:一项大型前瞻性单机构研究

Methylprednisolone Following Minimally Invasive Lumbar Decompression: A Large Prospective Single-Institution Study.
PubMed 文献 · Spine (Phila Pa 1976) · 2023-04-24

这项前瞻性随机单机构研究纳入486例微创腰椎减压术患者,随访平均5.17年,比较术中硬膜外注射甲泼尼龙与不用药的效果。结果显示两组疼痛无差异,但激素组2周时ODI降低(16.71 vs 21.02,P=0.04),主要见于术前ODI高的患者(13.00 vs 43.43,P=0.03),且激素组后续脊柱手术率更高。作者认为该技术可能最适合用于术前残疾明显的患者。

要点

  • 激素组与对照组在2周和4个月疼痛评分上无差异。
  • 激素组2周ODI降低(16.71 vs 21.02,P=0.04),4个月时无差异。
  • 术前ODI高者激素组ODI降幅更大(13.00 vs 43.43,P=0.03)。

核心结论

  • 甲泼尼龙硬膜外注射与术前ODI高的患者ODI大幅一过性降低相关,对疼痛无可测量效果。
  • 对后续再手术风险的影响不明确,作者认为该技术可能最适合用于术前残疾明显的患者。

研究设计与样本

  • 前瞻性随机研究,获IRB批准,研究期为2013年至2019年。
  • 随访了接受微创腰椎减压术中激素治疗与未接受激素治疗的数量接近的患者,共486例,平均随访5.17年。
  • 主要结局为2周和4个月的疼痛视觉模拟评分与ODI,次要结局为并发症、再入院和再手术率。

主要发现

  • 激素组索引病例更可能是翻修手术。
  • 所有患者中,2周和4个月疼痛无差异。
  • 激素组2周ODI降低(16.71 vs 21.02,P=0.04),4个月时无差异。
  • 亚组分析显示上述差异主要归因于术前ODI高的患者(13.00 vs 43.43,P=0.03)。
  • 激素组在研究期间更可能接受后续脊柱手术。

关键数值与推荐

  • 2周ODI:激素组16.71 vs 对照组21.02,P=0.04。
  • 术前ODI高者亚组ODI:激素组13.00 vs 对照组43.43,P=0.03。

临床怎么用

  • 作者认为该技术可能最适合用于术前残疾明显的患者。
  • 原文未据此给出其他推荐。

局限性

  • 既往研究多受样本量小和随访时间短的限制。
  • 激素组索引病例更可能是翻修手术。
  • 对后续再手术风险的影响不明确。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY DESIGN: Prospective randomized. OBJECTIVE: Intraoperative methylprednisolone is a common adjunct following microscopic laminectomy/microdiscectomy. The goal of epidural instillation is a rapid symptomatic reduction in irritation of neural elements. There is inconsistent data supporting its use intraoperatively. To understand whether this maneuver results in any clinical effect, we performed a multiyear prospective study. SUMMARY OF BACKGROUND DATA: Previous work has demonstrated equivocal effects on pain with a suggestion of an increased risk of complication. These studies tend to suffer from small sample sizes and short follow-ups. MATERIALS AND METHODS: Study obtained IRB approval. During the study period from 2013 to 2019, nearly equivalent numbers of patients who had received steroids during MIS decompressions were followed. Primary outcomes included pain (visual analog scale) and disability [Oswestry Disability Index (ODI)] at 2 weeks and 4 months. Secondary outcomes included complications, readmissions, and reoperation rates during the study period. RESULTS: Four hundred eighty-six patients were followed for a mean follow-up of 5.17 years. The index case was more likely to be a revision surgery in the steroid group. Across all patients, there was no difference in pain at 2 weeks or 4 months. Disability was reduced at 2 weeks in the steroid group (ODI: 16.71 vs . 21.02, P = 0.04) but not at 4 months. By subgroup analysis, this is largely explained by ODI reduction in patients with high preoperative ODI (13.00 vs . 43.43, P = 0.03). Patients in the steroid cohort were more likely to undergo subsequent spinal surgery during the study period. CONCLUSION: Methylprednisolone instillation is associated with a large, transient reduction in ODI for patients with high preoperative ODI; there is no measurable effect on pain. There is equivocal effect on risk of subsequent reoperation. This issue was clarified in peer review but changes did not make it to the abstract. Therefore, the technique is likely best reserved for patients with significant preoperative disability.

来源:Spine (Phila Pa 1976),查看原文。版权归原作者所有。

引用

  1. Florence TJ, Say I, Rivera J, et al. Methylprednisolone Following Minimally Invasive Lumbar Decompression: A Large Prospective Single-Institution Study. Spine (Phila Pa 1976). 2023. PMID: 37093030. doi:10.1097/BRS.0000000000004660

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。